|
US2033909A
(en)
|
1934-12-19 |
1936-03-17 |
Niacet Chemicals Corp |
Manufacture of calcium levulinate
|
|
CA1197242A
(en)
*
|
1983-03-02 |
1985-11-26 |
Jean A. Gauthier |
Pyrimido¬1,2-a|pyrrolo¬2,1-c|¬1, 4|benzodiazepine-3-carboxylic acid derivatives
|
|
US4691034A
(en)
|
1986-04-14 |
1987-09-01 |
Texaco, Inc. |
Purification of propylene oxide by treatment with calcium hydroxide in glycerol or sugar water
|
|
US5166174A
(en)
|
1987-01-28 |
1992-11-24 |
K.K. Ueno Seiyaku Oyo Kenkyujo |
Prostaglandins E and anti-ulcers containing same
|
|
US5133974A
(en)
|
1989-05-05 |
1992-07-28 |
Kv Pharmaceutical Company |
Extended release pharmaceutical formulations
|
|
US5648387A
(en)
*
|
1995-03-24 |
1997-07-15 |
Warner-Lambert Company |
Carboxyalkylethers, formulations, and treatment of vascular diseases
|
|
EP1017390B1
(en)
|
1997-07-31 |
2007-04-18 |
Kos Life Sciences, Inc. |
Coated tablet comprising nicotinic acid or a compound metabolized to nicotinic acid in an extended release form, and a coating containing an hmg-coa reductase inhibitor in an immediate release form
|
|
US6861555B2
(en)
*
|
2000-01-25 |
2005-03-01 |
Warner-Lambert Company |
Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
|
|
US6459003B1
(en)
|
1999-04-01 |
2002-10-01 |
Esperion Therapeutics, Inc. |
Ether compounds
|
|
NZ519550A
(en)
|
2000-01-25 |
2003-11-28 |
Warner Lambert Co |
Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
|
|
US6500457B1
(en)
|
2000-08-14 |
2002-12-31 |
Peirce Management, Llc |
Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
|
|
CN100376570C
(zh)
|
2000-10-13 |
2008-03-26 |
希拉生物化学股份有限公司 |
改善胞间传输的二氧戊环类似物
|
|
HUP0400381A2
(hu)
|
2001-06-29 |
2004-09-28 |
Warner-Lambert Company Llc |
[R-(R*,R*)]-2-(4fluorfenil)-béta, delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)karbonil]-1H-pirrol-1-heptánsav 2:1 arányú kalciumsójának (atorvasztatin) kristályos formái
|
|
US20040192771A1
(en)
|
2001-10-11 |
2004-09-30 |
Dasseux Jean-Louis Henri |
Ether compounds and compositions for cholesterol management and related uses
|
|
DE10211289A1
(de)
|
2002-03-14 |
2003-09-25 |
Basf Ag |
Kombination von Polyvinylacetat von wasserunlöslichen, säureunlöslichen oder alkaliunlöslichen Polymeren zur Hestellung von Filmüberzügen mit sehr kontrollierter Freisetzung und hoher Stabilität
|
|
WO2003088962A1
(en)
|
2002-04-16 |
2003-10-30 |
Merck & Co., Inc. |
Combination therapy using a ppar alpha/gamma agonist
|
|
AU2003227691B2
(en)
|
2002-05-03 |
2008-05-15 |
Hexal Ag |
Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
|
|
JP2006501238A
(ja)
|
2002-08-22 |
2006-01-12 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
骨関節炎を治療する方法
|
|
WO2004045596A1
(en)
|
2002-11-15 |
2004-06-03 |
Warner-Lambert Company Llc |
Method of lowering crp and reducing systemic inflammation
|
|
ES2645930T3
(es)
|
2003-01-03 |
2017-12-11 |
Supernus Pharmaceuticals, Inc. |
Utilización de una mezcla de dos o más materiales entéricos para regular la liberación de fármacos a través de una membrana o matriz para terapias sistémicas
|
|
WO2005002557A1
(en)
|
2003-07-03 |
2005-01-13 |
Warner-Lambert Company Llc |
Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof
|
|
US20050026979A1
(en)
|
2003-07-31 |
2005-02-03 |
Maha Ghazzi |
Methods for treating inflammation and inflammation-associated diseases with a statin and ether
|
|
US7345190B2
(en)
|
2003-11-12 |
2008-03-18 |
Ssv Therapeutics, Inc. |
Carnitine conjugates as dual prodrugs and uses thereof
|
|
WO2006054308A2
(en)
|
2004-11-22 |
2006-05-26 |
Dexcel Pharma Technologies Ltd. |
Stable atorvastatin formulations
|
|
FR2891459B1
(fr)
|
2005-09-30 |
2007-12-28 |
Flamel Technologies Sa |
Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
|
|
CA2628666A1
(en)
|
2005-11-21 |
2007-05-24 |
Teva Pharmaceutical Industries Ltd. |
Atorvastatin formulation
|
|
CN104825397A
(zh)
|
2006-04-03 |
2015-08-12 |
伊萨·奥迪迪 |
含有机溶胶涂层的受控释放递送物件
|
|
US7777071B2
(en)
|
2006-08-11 |
2010-08-17 |
Ssv Therapeutics, Inc. |
Production of carnitine conjugate intermediates
|
|
US20080241240A1
(en)
|
2006-08-24 |
2008-10-02 |
Hanall Pharmaceutical Co., Ltd. |
Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
|
|
WO2008022932A2
(en)
|
2006-08-25 |
2008-02-28 |
Boehringer Ingelheim International Gmbh |
Controlled release system and method for manufacturing the same
|
|
FI20080353A0
(fi)
|
2008-05-09 |
2008-05-09 |
Atacama Labs Oy |
Prosessi erittäin korkean lääkepitoisuuden tabletin valmistamiseksi
|
|
US9486446B2
(en)
|
2006-12-28 |
2016-11-08 |
Takeda Pharmaceutical Company Limited |
Orally disintegrating solid preparation
|
|
CZ300047B6
(cs)
|
2007-03-02 |
2009-01-21 |
Zentiva, A. S. |
Farmaceutická kompozice s obsahem úcinné látky atorvastatinu
|
|
WO2008124505A2
(en)
|
2007-04-05 |
2008-10-16 |
Ironwood Pharmaceuticals,Inc. |
Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
US20090036414A1
(en)
|
2007-08-02 |
2009-02-05 |
Mutual Pharmaceutical Company, Inc. |
Mesalamine Formulations
|
|
WO2009024889A2
(en)
|
2007-08-21 |
2009-02-26 |
Ranbaxy Laboratories Limited |
Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
|
|
WO2009048938A1
(en)
|
2007-10-08 |
2009-04-16 |
Keen Ingredients, Inc. |
Quinoa grain processing and products
|
|
BRPI0822026B8
(pt)
|
2008-01-10 |
2021-05-25 |
Evonik Roehm Gmbh |
preparação farmacêutica ou nutracêutica, comprimido, gelatina ou cápsula de hpmc, e uso de uma ou uma mistura de uma pluralidade de polímeros ou copolímeros
|
|
US20090226515A1
(en)
|
2008-03-04 |
2009-09-10 |
Pharma Pass Ii Llc |
Statin compositions
|
|
FR2928925B1
(fr)
|
2008-03-19 |
2011-01-07 |
Centre Nat Rech Scient |
Complexes de bore ou d'aluminium, et leurs utilisations.
|
|
EP2285352A2
(en)
|
2008-05-13 |
2011-02-23 |
Dr. Reddy's Laboratories Ltd. |
Atorvastatin compositions
|
|
RU2010151944A
(ru)
|
2008-05-20 |
2012-06-27 |
Серенис Терапьютикс С.А. (Fr) |
Ниацин и нспвс для комбинированной терапии
|
|
RU2404767C1
(ru)
|
2009-08-11 |
2010-11-27 |
Закрытое Акционерное Общество "БИОКОМ" |
Твердая лекарственная форма, обладающая гиполипидемической и гипохолестеринемической активностью, и способ ее получения
|
|
AU2011270719B2
(en)
|
2010-06-24 |
2015-09-24 |
Arisaph Pharmaceuticals, Inc. |
Niacin mimetics, and methods of use thereof
|
|
TR201005325A2
(tr)
|
2010-06-30 |
2012-01-23 |
Bi̇lgi̇ç Mahmut |
Atorvastatin ve aspirin içeren farmasötik formülasyonlar
|
|
PL2592081T3
(pl)
|
2010-07-06 |
2017-07-31 |
Ono Pharmaceutical Co., Ltd. |
Pochodna tetrahydrokarboliny
|
|
TW201304823A
(zh)
|
2010-12-27 |
2013-02-01 |
Takeda Pharmaceutical |
口腔內崩壞錠
|
|
ES2608177T3
(es)
|
2010-12-27 |
2017-04-06 |
Gemphire Therapeutics Inc. |
Gemcabeno y derivados para el tratamiento de la pancreatitis
|
|
UA112539C2
(uk)
|
2011-03-03 |
2016-09-26 |
Новартіс Аг |
Спосіб одержання похідних 2-карбоксамідциклоаміносечовини
|
|
CA2835293C
(en)
*
|
2011-06-08 |
2020-08-18 |
Sti Pharma, Llc |
Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
|
|
RU2491070C2
(ru)
|
2011-10-11 |
2013-08-27 |
Общество с ограниченной ответственностью "Фармамед" |
Фармацевтическая композиция для профилактики и лечения сердечно-сосудистых заболеваний
|
|
EP2787986B1
(en)
|
2011-12-08 |
2017-10-18 |
Syndromex Ltd. |
Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof
|
|
EP2604256B1
(en)
|
2011-12-14 |
2016-04-13 |
Hexal AG |
Multi layer coatings
|
|
JP6295205B2
(ja)
*
|
2012-01-06 |
2018-03-14 |
ジェムファイア セラピューティクス インクGemphire Therapeutics Inc. |
心血管疾患のリスクを低減する方法
|
|
CN104127391B
(zh)
|
2014-08-05 |
2016-08-24 |
李宝齐 |
一种含有阿托伐他汀钙的固体药物组合物
|
|
EP3218349A2
(en)
*
|
2014-11-14 |
2017-09-20 |
Gemphire Therapeutics Inc. |
Processes and intermediates for preparing , -dicarboxylic acid-terminated dialkane ethers
|
|
MX2018005096A
(es)
*
|
2015-11-06 |
2018-08-15 |
Gemphire Therapeutics Inc |
Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular.
|
|
CN105434391A
(zh)
|
2016-01-18 |
2016-03-30 |
上海蓝心医药科技有限公司 |
阿托伐他汀钙肠溶片及其制备方法和应用
|
|
EP3612171A4
(en)
|
2017-04-18 |
2020-10-21 |
Gemphire Therapeutics Inc. |
GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND PROCEDURES FOR THE USE OF THE SAME
|
|
WO2018209257A1
(en)
|
2017-05-11 |
2018-11-15 |
Gemphire Therapeutics Inc. |
Gemcabene compositions and methods of use thereof
|